Mod GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-08. Numbers and descriptions here follow the published literature rather than marketing material.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
=== Primary cold agglutinin disease === The primary form is caused by excessive cell proliferation of B lymphocytes, characterized by clonal lymphoproliferative disorder. Primary cold agglutinin disease occurs after the fifth decade of life and peaks prevalence in a person's 70s and 80s.
Renin is usually measured as the plasma renin activity (PRA). PRA is measured specially in case of certain diseases that present with hypertension or hypotension. PRA is also raised in certain tumors. A PRA measurement may be compared to a plasma aldosterone concentration (PAC) as a PAC/PRA ratio.
== Biosynthesis == Prostaglandin E1 is biosynthesized on an as-needed basis from dihomo-γ-linolenic acid (an omega-6 fatty acid) in healthy humans without coronary artery disease and/or a genetic disorder.
=== 1950 === January 5: The UK recognizes the People's Republic of China. The Republic of China severs diplomatic relations with the United Kingdom. January 13: Because of the failure to replace Taiwan with the People's Republic of China in the United Nations Security Council the Soviet Union boycotts the United Nations by having their diplomat Yakov Malik not attend any United Nations Security Council meetings. January 18: China officially recognizes the Democratic Republic of Vietnam. January 21: The last Kuomintang soldiers surrender on continental China. January 31: President Truman announces the beginning of the development of a hydrogen bomb. February 3: Soviet Union establishes diplomatic relations with Indonesia through an exchange of telegrams between Indonesian Vice-president, Mohammad Hatta and Soviet Foreign Minister Andrey Vyshinsky. February 7: The UK and the US recognize the State of Vietnam. February 9: Senator Joseph McCarthy first claims without evidence that Communists have infiltrated the U.S. State Department, leading to a controversial series of anti-Communist investigations in the United States. February 12: The Soviet Union and the People's Republic of China sign a pact of mutual defense. March 11: Kuomintang leader Chiang Kai-shek moves his capital to Taipei, Taiwan, establishing a stand-off with the People's Republic of China. April 7: United States State Department Director of Policy Planning Paul Nitze issues NSC 68, a classified report, arguing for the adoption of containment as the cornerstone of United States foreign policy.
A sperm bank will aim to provide donor sperm that is safe by screening donors and their semen. A sperm donor must generally meet specific requirements regarding age and medical history. Requirements for sperm donors are generally strictly enforced; in a study of 24,040 potential sperm donors, only 5,620 (23.38%) were eligible to donate their sperm. Sperm banks typically screen potential donors for a range of diseases and disorders, including genetic diseases, chromosomal abnormalities, and sexually transmitted infections that may be transmitted through sperm. Donors are generally subject to tests for infectious diseases such as human immunoviruses HIV (HIV-1 and HIV-2), human T-cell lymphotropic viruses (HTLV-1 and HTLV-2), syphilis, chlamydia, gonorrhea, hepatitis B virus, hepatitis C virus, cytomegalovirus (CMV), Trypanosoma cruzi and malaria as well as hereditary diseases such as cystic fibrosis, sickle cell anemia, familial Mediterranean fever, Gaucher's disease, thalassaemia, Tay–Sachs disease, Canavan's disease, familial dysautonomia, congenital adrenal hyperplasia, carnitine transporter deficiency. Some sperm banks may also use karyotyping to ensure donors are 46XY. Some sperm banks disallow sexually active gay men from donating sperm due to the population's increased risk of HIV and hepatitis B. The screening procedure generally also includes a quarantine period, in which the samples are frozen and stored for at least six months after which the donor will be re-tested for the STIs.
Sources: en.wikipedia.org
=== Proton pumps === A proton pump is any process that creates a proton gradient across a membrane. Protons can be physically moved across a membrane, as seen in mitochondrial Complexes I and IV. The same effect can be produced by moving electrons in the opposite direction. The result is the disappearance of a proton from the cytoplasm and the appearance of a proton in the periplasm. Mitochondrial Complex III is this second type of proton pump, which is mediated by a quinone (the Q cycle). Some dehydrogenases are proton pumps, while others are not. Most oxidases and reductases are proton pumps, but some are not. Cytochrome bc1 is a proton pump found in many, but not all, bacteria (not in E. coli). As the name implies, bacterial bc1 is similar to mitochondrial bc1 (Complex III).
The Life Sciences Institute (LSI) is a collaborative, multidisciplinary research institution located on the campus of the University of Michigan in Ann Arbor. It encompasses 27 faculty-led teams from 13 schools and departments throughout U-M. Of the university's $823 million in research expenditures, more than half is allocated for research in the life sciences, and the LSI is a cornerstone of this effort.
LEDs are used in mining operations, as cap lamps to provide light for miners. Research has been done to improve LEDs for mining, to reduce glare and to increase illumination, reducing risk of injury to the miners. LEDs are increasingly finding uses in medical and educational applications, for example as mood enhancement. NASA has even sponsored research for the use of LEDs to promote health for astronauts.
In 1958, British developmental psychologist John Bowlby published the paper "the Nature of the Child's Tie to his Mother," in which the precursory concepts of "attachment theory" were developed. This included the development of the concept of the affectional bond, which is based on the universal tendency for humans to attach, i.e. to seek closeness to another person and to feel secure when that person is present. Attachment theory has some of its origins in the observation of and experiments with animals, but is also based on observations of children who had missed typical experiences of adult care. Much of the early research on attachment in humans was done by John Bowlby and his associates. Bowlby proposed that babies have an inbuilt need from birth to make emotional attachments, i.e. bonds, because this increases the chances of survival by ensuring that they receive the care they need. Bowlby did not describe mutuality in attachment. He stated that attachment by mother was a pathological inversion and described only behaviors of the infant. Many developmental specialists elaborated Bowlby's ethological observations. However, neither Bowlby's proximity seeking (not possible for human infants prior to walking) nor subsequent descriptions of caregiver–infant mutuality with emotional availability and synchrony with emotional modulation include the enduring motivation of attachment into adult life. The enduring motivation is the desire to control a pleasantly surprising transformation that is the route of belief in effectiveness by humans.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.